hydradenitis suppurativa

After a Phase 2 flop, Brinsupri exits the race to market for the chronic skin disease hidradenitis suppurativa, but other companies, including Incyte, Novartis and UCB, have recently notched clinical ... MarketWatch: Insmed to Discontinue Brensocatib Program for Hidradenitis Suppurativa After Trial Misses Endpoints The biopharmaceutical company on Tuesday said adult patients with moderate to severe hidradenitis suppurativa experienced a roughly 46% percent reduction in total abscesses and inflammatory nodules ... Insmed to Discontinue Brensocatib Program for Hidradenitis Suppurativa After Trial Misses Endpoints The American Journal of Managed Care: Long-Term Bimekizumab Data Confirm Sustained Efficacy, Consistent Safety in Hidradenitis Suppurativa: Steven Daveluy, MD Long-Term Bimekizumab Data Confirm Sustained Efficacy, Consistent Safety in Hidradenitis Suppurativa: Steven Daveluy, MD Investing.com -- Insmed Incorporated (NASDAQ:INSM) fell 2% in after-hours trading Tuesday after the company announced it would discontinue its hidradenitis suppurativa program following a failed Phase ...